In ovarian cancer, tumor-driven unremitting expression of Satb1 was reported to enhance Galectin-1 and interleukin 6 (IL-6) production in activated inflammatory DCs, resulting in immune suppression and contributing to malignant progression [44]. Here, IL6 is linked to ovarian carcinoma.